Qilu Drug Research Institute is mainly engaged in the research and development of chemical drugs and biotechnology drugs for the treatment of tumors, cardiovascular and cerebrovascular diseases, infections, and psychiatric and neurological diseases. The company adheres to the innovative development strategy of "taking the enterprise as the main body, market as the guide, and relying on the close integration of industry, academia and research", and based on imitation, it continues to expand the field of innovative drug research. We carry out extensive cooperation at home and abroad, focus on the introduction and training of talents, and have a high-quality scientific research team and professional and efficient R&D capabilities. More than one hundred chemical and biotechnological drugs, including multiple new molecular entities, are in various stages, including clinical studies. The company has formed a virtuous cycle of research and production, laying a solid foundation for the development of the enterprise. Innovation platform Qilu Drug Research Institute is now a national enterprise technology center, with the "National Engineering Laboratory for Efficient Expression of Mammalian Cells", the "Provincial Key Laboratory of New Technology for Injectable Microparticle Delivery", and the "Provincial Key Laboratory of Small Molecule Targeted Drugs" Laboratory", has set up Taishan scholar positions for "targeted drug research and development", and has the title of Jinan City's "Excellent Innovation Team for Small Molecule Targeted Anti-tumor Drugs". Over the past twenty years, Qilu Pharmaceutical Research Institute has obtained more than 100 new drug certificates and successfully developed monosialotetrahexosylganglioside, pemetrexed, docetaxel, carboplatin, and recombinant human IL -11. Dozens of blockbuster new drugs such as recombinant human G-CSF, ondansetron, palonosetron, levosimendan, and Tigeol have laid a solid product foundation for the company's development; apply for invention patents More than 100 projects have been completed; many studies have been awarded national and provincial science and technology progress awards; and it has undertaken 17 major national science and technology special projects for the creation of major new drugs. Talent echelon In the development of more than 20 years, Qilu Pharmaceutical Research Institute is based on its own, eclectic and inclusive, and recruits people of insight at home and abroad. It has built a drug research and management team with complete expertise, reasonable structure, and an international perspective in drug research. . The Institute of Drug Research has nearly 600 researchers, 30 with doctoral degrees and about 230 with master's degrees, including 10 with long-term drug research experience abroad. Foreign Cooperation Qilu Pharmaceutical Research Institute has established extensive contacts with domestic and foreign research institutions, universities, CRO companies, etc., and has carried out all-round cooperation. The flexible and diverse cooperation methods determined according to project research needs effectively promote the rapid progress of drug research and provide strong support for improving the team's research level.